Submit Your Article CMED MEACR meeting
Home Print this page Email this page Users Online: 162
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
ORIGINAL ARTICLE
Year : 2020  |  Volume : 9  |  Issue : 3  |  Page : 84-88

Coexistence of ten-eleven translocation 2 and calreticulin mutations in myeloproliferative neoplasms: Possible prognostic value


Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Date of Submission03-Dec-2019
Date of Decision26-Feb-2020
Date of Acceptance10-Apr-2020
Date of Web Publication16-Jun-2020

Correspondence Address:
Najmaldin Saki
Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ccij.ccij_114_19

Rights and Permissions
  Abstract 


Background: Mutations in the genes regulating epigenetic factors such as Ten-Eleven Translocation 2 (TET2) along with other mutations are highly effective in the patient's prognosis. The aim of this study was to evaluate the prevalence of TET2 and calreticulin (CALR) mutations among myeloproliferative neoplasms (MPNs) patients to determine if there is a prognostic value for these mutations coexistence. Materials and Methods: Blood sample was collected from patients. For the evaluation of mutations, polymerase chain reaction (PCR) was performed on the patient's DNA and PCR products were subsequently sequenced. Results: No significant correlation between coexistence of TET2 and CALR mutations with complete blood count parameters in patients was seen. However, platelet count was lower in patients with TET2 and CALR mutations compared with patients with CALR mutations only. Conclusion: The coexistence of CALR and TET2 mutations in MPN patients can be used as a prognostic factor.

Keywords: Calreticulin, Janus kinase 2, mutation, myeloproliferative neoplasms, Ten-Eleven Translocation 2


How to cite this article:
Bagherpour S, Vosoughi T, Birgani MT, Ehsanpour A, Saki N. Coexistence of ten-eleven translocation 2 and calreticulin mutations in myeloproliferative neoplasms: Possible prognostic value. Clin Cancer Investig J 2020;9:84-8

How to cite this URL:
Bagherpour S, Vosoughi T, Birgani MT, Ehsanpour A, Saki N. Coexistence of ten-eleven translocation 2 and calreticulin mutations in myeloproliferative neoplasms: Possible prognostic value. Clin Cancer Investig J [serial online] 2020 [cited 2020 Jul 7];9:84-8. Available from: http://www.ccij-online.org/text.asp?2020/9/3/84/286827




  Introduction Top


Although recent results have indicated that mutation in genes involved in signaling pathways such as Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus (MPL) is a major reason for the incidence of myeloproliferative neoplasms (MPNs), the latest findings have shown that the mutations in genes involved in epigenetic regulation and so disruption of epigenetic processes and DNA methylation play an essential role in the occurrence of abnormalities in replication, differentiation, and expression of genes in MPNs, which can be considered as a key factor in the onset of disease.[1],[2],[3] Ten-Eleven Translocation 2 (TET2) is a member of TET family of proteins whose encoding gene has 13 exons and lies in 4q24 locus. The expression of TET2 is different in various cells, but it seems to be highly expressed in hematopoietic cells.[2],[4],[5],[6]TET2 has catalytic activity and plays a crucial role in the process of 5-methylcytosine conversion to 5-hydroxymethylcytosine (5-hmC), controlling the expression of genes through epigenetic processes. Mutation in TET2 decreases 5-hmC production and subsequently increases DNA methylation.[7],[8],[9] Various mutations such as missense, nonsense, and frameshift occur in TET2, which are randomly distributed across all TET2 exons; nevertheless, a majority of mutations occurs in exons 4 and 12. These mutations have been identified in several hematological malignancies, including MPNs, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML).[10],[11] Some recent studies have shown that mutations in TET2 by itself cannot be considered as a factor of malignancy but have been detected in many hematologic malignancies along with mutations in other genes such as JAK2, MPL, and FLT3.[12] As well as somatic mutations in exon 9 of CALR gene were identified in a majority of patients with ET and primary myelofibrosis (PMF) who were negative for JAK2 and MPL mutations that are known as driver mutations for MPN. It has also been noted that MPN patients with mutations in CALR have better clinical outcomes and survival than those with mutations in JAK2 or MPL. It was found that initially CALR mutations occur in about 70% of MPN patients who do not have mutations in JAK2 and MPL.[13] However, co-occurrence of both the mutations has been reported in few MPN patients. Nonetheless, precise studies have not been conducted to detect mutations in both TET2 and CALR genes in MPNs. Hence, mutations in TET2 and CALR genes appear to cause changes in blood cell count and response to treatment in patients. Therefore, for the first time, we examined TET2 and CALR mutations in MPN patients and their association with hematological parameters of patients in this study.


  Materials and Methods Top


Patients

In a year period (since 2017 August until 2018 September), all MPNs patients who referred to Shafa Hospital of Ahvaz, Southwest of Iran (including 260 persons), were evaluated for JAK2 and CALR mutations. After collection and analysis of 5 ml peripheral blood from each patient that was collected in ethylenediaminetetraacetic acid, 212 patients who had JAK2 mutations were excluded from the study. Since our studies inclusion criteria were the presence of CALR mutation and no previous history of treatment, patients lacking CALR mutation were excluded. Finally, 19 patients who had CALR mutation were recruited for our study, including 14 patients with essential thrombocythemia (ET) and 5 PMF patients [Figure 1]. Diagnosis of patients was based on the World Health Organization criteria.[14]
Figure 1: Flow diagram showing patient selection and exclusion

Click here to view


We obtained ethical approval for the study from the local ethics committee of Ahvaz Jundishapur University of Medical Science (IBR Number: IR. AJUMS. REC.1396.733).

Polymerase chain reaction and sequencing

DNA extraction from samples was performed using salting out method,[15] and polymerase chain reaction (PCR) was performed using specific primers [Table 1] to amplify exon 4 and 12 mutations. The PCR reaction was carried out in a total volume of 25 μl containing 1× reaction buffer, dNTP (0.25 mM), primer (2 pmol/), genomic DNA templates (0.4 μg), and Taq DNA polymerase (1.5 U). Thermocycler was programmed as first denaturation for 3 min at 95°C followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 60°C for 30 s, extension at 72°C for 30 s, and final extension at 72°C for 4 min. Negative control was considered in each PCR reaction which defined as a sample without a DNA template. All the PCR products were checked on 1.5% agarose gel electrophoresis staining with safe stain, and product bands were visualized under ultraviolet light. Subsequently, PCR products were sequenced by the Sanger method.
Table 1: Primers used for analysis Ten-Eleven Translocation 2 mutations

Click here to view


Statistical analysis

The results were fed into SPSS version 20 software (IBM, Armonk, NY, USA), and statistical analysis was conducted using t-test, Chi-square, and Kolmogorov–Smirnov tests. Statistical significance was indicated as P ≤ 0.05.


  Results Top


Patient information

From 19 patients with CALR mutation, 14 patients were afflicted with ET and had an average age of 52.71 (range: 32–76) and the remaining five patients had PMF with an average age of 51.20 (range: 43–58 years). Moreover, 12 patients were male and 7 were female. Data on laboratory and hematological parameters of these patients that were recorded at the time of diagnosis are presented in [Table 2], including hemoglobin (Hb), red blood cell (RBC), white blood cell (WBC), and platelet [Table 2].
Table 2: Disease type, gender, age, and cell count information of 19 recruited patients

Click here to view


Prevalence of Ten-Eleven Translocation 2 gene mutations in calreticulin-positive patients

After analysis of samples, it was found that 35.7% of the ET patients had mutation in TET2 gene, 7.1% of whom showed mutations in exon 4, 21.4% in exon 12, and 7.1% in both exons 4 and 12. On the other hand, 80% of PMF patients had mutations in TET2 gene, among whom 20% showed mutation in exon 4, 40% in exon 12, and 20% in both exons 4 and 12 [Table 3].
Table 3: Frequency of Ten-Eleven Translocation 2 mutations in patients

Click here to view


Correlation between Ten-Eleven Translocation 2 mutations with hematological parameters

After investigations, no significant correlation was found between Hb (P = 0.347), RBC (P = 0.117), and WBC (P = 0.329) with mutations occurring in TET2 gene. However, platelet count was lower in patients with a mutation in TET2 gene compared to those without mutation in it, which was statistically significant (P = 0.03) [Table 4] and [Table 5].
Table 4: Association between Ten-Eleven Translocation 2 mutation and hematological parameters in calreticulin mutated patients

Click here to view
Table 5: Association between Ten-Eleven Translocation 2 mutation and platelet count in studied patients

Click here to view



  Discussion Top


MPNs are disorders characterized by imbalance in the production of erythroid series, which leads to monoclonal production of a specific series and suppression of others.[16],[17],[18] MPNs are divided into three groups: polycythemia vera, essential thrombocythaemia (ET), and PMF. MPNs are different in terms of clinical symptoms so that some patients have no complications and others develop advanced disease causing secondary AML.[19],[20],[21] Furthermore, 75% of the MPN patients have JAK2V617F mutation and most of the time show similar molecular manifestations. Nonetheless, a diagnostic challenge is created when patients lack the JAK2V617F mutation.[22],[23],[24] Hence, recent studies have shown that identification of new mutations can be effective in differentiating between MPNs as well as determining the prognosis based on mutations for treatment of disease. TET2 is a factor controlling the expression of many genes by regulating epigenetic processes. Investigations have shown that mutation in TET2 gene alone cannot lead to malignancy. Therefore, the coexistence of TET2 gene mutation along with mutation in other genes has been shown in many malignancies.[25],[26] To this end, in a study by Delic et al., it was found that the frequency of mutations in the genes encoding epigenetic process regulators such as TET2, IDH1 and 2, and DNMT3A was higher in PMF patients than in ET patients.[27] Furthermore, in a study by Ivanova et al. on 16 MPN patients, seven patients had mutations in ASXL1, CALR, RUNX1, SRSF2, TET2, and U2AF1 genes.[28] In the current study, however, only 47.4% of the PMF patients had mutations in both CALR and TET2 genes, and the frequency of mutation in exons 4 and 12 of TET2 gene in PMF patients was higher than ET patients. In addition, the prevalence of the mutation in exon 12 compared to exon 4 was higher in both groups of PMF and ET patients [Table 3]. Studies have shown that the coexistence of mutations in MPN patients can affect the progression of disease, as well as prognosis and response to treatment. For this purpose, in the study of Limsuwanachot et al., it was found that platelet count was significantly higher in ET patients lacking CALR mutation relative to those carrying CALR mutation, which was statistically significant (P = 0.04). In addition to platelets, Hb and WBC were higher in nonmutated patients compared to those with CALR mutation, which was statistically significant (P = 0.01 for Hb and P = 0.04 for WBC).[29] Moreover, in the study of Ha et al.,[30] it was found that platelet count was higher in PMF and ET patients with TET2 mutation than those without TET2 mutation, but no significant relationship was found between them (P = 0.2 for ET and P = 0.05 for PMF). In PMF patients, WBC count was higher in those with mutation in TET2 compared to those lacking it, which was statistically significant (P = 0.03). On the other hand, among ET patients, it was also found that those with TET2 mutation had higher WBC count than nonmutated ones, which was not statistically significant (P = 0.4).[10] In our study, platelet count was found to be lower in patients with mutation in TET2 than those lacking TET2 mutation, which was statistically significant (P = 0.039). In contrast, there was no significant difference between the levels of RBC, Hb, and WBC with TET2 mutation among patients [Table 5].


  Conclusion Top


According to the present study, given the decrease in platelet count in patients having TET2 and CALR mutation, it can be argued that the coexistence of CALR and TET2 mutations can be considered as a prognostic factor in MPNs patients.

Acknowledgments

We wish to thank all our colleagues at Shafa Hospital and Allied Health Sciences School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Financial support and sponsorship

This work was financially supported by grant TH96/11 from vice chancellor for research affairs of Ahvaz Jundishapur University of Medical Science. This article is issued from the thesis of Soheila Bagherpour.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Bowman RL, Levine RL. TET2 in normal and malignant hematopoiesis. Cold Spring Harb Perspect Med 2017;7:a026518.  Back to cited text no. 1
    
2.
Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. The ten-eleven translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 2014;28:485-96.  Back to cited text no. 2
    
3.
Viny AD, Levine RL. Genetics of myeloproliferative neoplasms. Cancer J 2014;20:61-5.  Back to cited text no. 3
    
4.
Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144-7.  Back to cited text no. 4
    
5.
Langemeijer SM, Aslanyan MG, Jansen JH. TET proteins in malignant hematopoiesis. Cell Cycle 2009;8:4044-8.  Back to cited text no. 5
    
6.
Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-38.  Back to cited text no. 6
    
7.
Chiba S. Dysregulation of TET2 in hematologic malignancies. Int J Hematol 2017;105:17-22.  Back to cited text no. 7
    
8.
Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 2011;108:14566-71.  Back to cited text no. 8
    
9.
Zhao Z, Chen S, Zhu X, Pan F, Li R, Zhou Y, et al. The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells. Leukemia 2016;30:1784-8.  Back to cited text no. 9
    
10.
Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009;114:1628-32.  Back to cited text no. 10
    
11.
Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343-5.  Back to cited text no. 11
    
12.
Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 2015;126:790-7.  Back to cited text no. 12
    
13.
McPherson S, McMullin MF, Mills K. Epigenetics in myeloproliferative neoplasms. J Cell Mol Med 2017;21:1660-7.  Back to cited text no. 13
    
14.
Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion. Blood Cancer J 2018;8:15.  Back to cited text no. 14
    
15.
Magiera S, Kolanowska A, Baranowski J. Salting-out assisted extraction method coupled with hydrophilic interaction liquid chromatography for determination of selected β-blockers and their metabolites in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1022:93-101.  Back to cited text no. 15
    
16.
Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 2017;129:680-92.  Back to cited text no. 16
    
17.
Saeidi K. Myeloproliferative neoplasms: Current molecular biology and genetics. Crit Rev Oncol Hematol 2016;98:375-89.  Back to cited text no. 17
    
18.
Them NC, Kralovics R. Genetic basis of MPN: Beyond JAK2-V617F. Curr Hematol Malig Rep 2013;8:299-306.  Back to cited text no. 18
    
19.
Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin Oncol 2011;29:3179-84.  Back to cited text no. 19
    
20.
Crisà E, Venturino E, Passera R, Prina M, Schinco P, Borchiellini A, et al. A retrospective study on 226 polycythemia vera patients: Impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol 2010;89:691-9.  Back to cited text no. 20
    
21.
Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: Contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 2009;6:627-37.  Back to cited text no. 21
    
22.
Alvarez-Larran A, Martínez D, Arenillas L, Rubio A, Arellano-Rodrigo E, Hernández Boluda JC, et al. Essential thrombocythaemia with mutation in MPL: Clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes. J Clin Pathol 2018;71:975-80.  Back to cited text no. 22
    
23.
McLornan D, Percy M, McMullin MF. JAK2 V617F: A single mutation in the myeloproliferative group of disorders. Ulster Med J 2006;75:112-9.  Back to cited text no. 23
    
24.
Rashid M, Ahmed RZ, Ahmed S, Nadeem M, Ahmed N, Shamsi TS. Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia. Indian J Hematol Blood Transfus 2016;32:112-6.  Back to cited text no. 24
    
25.
Delhommeau F, Dupont S, James C, Masse A, Le Couedic JP, Valle VD, et al. TET2 is a novel tumor suppressor gene inactivated in myeloproliferative neoplasms: Identification of a Pre-JAK2 V617F Event. Blood 2008;112:lba-3.  Back to cited text no. 25
    
26.
Pan F, Weeks O, Yang FC, Xu M. The TET2 interactors and their links to hematological malignancies. IUBMB Life 2015;67:438-45.  Back to cited text no. 26
    
27.
Delic S, Rose D, Kern W, Nadarajah N, Haferlach C, Haferlach T, et al. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Br J Haematol 2016;175:419-26.  Back to cited text no. 27
    
28.
Ivanova M, Shivarov V, Pavlov I, Lilakos K, Naumova E. clinical evaluation of a novel nine-gene panel for ion torrent PGM sequencing of myeloid malignancies. Mol Diagn Ther 2016;20:27-32.  Back to cited text no. 28
    
29.
Limsuwanachot N, Rerkamnuaychoke B, Chuncharunee S, Pauwilai T, Singdong R, Rujirachaivej P, et al. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients. Hematology 2017;22:599-606.  Back to cited text no. 29
    
30.
Ha JS, Jeon DS, Kim JR, Ryoo NH, Suh JS. Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms. Ann Clin Lab Sci 2014;44:173-9.  Back to cited text no. 30
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Materials and Me...
Results
Discussion
Conclusion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed75    
    Printed2    
    Emailed0    
    PDF Downloaded1    
    Comments [Add]    

Recommend this journal